Figure 2.
OS and PFS in the overall LUX-Lung 8 population (n=795).
Notes: (A) OS; (B) PFS. Reprinted from Lancet Oncol, vol 16(8). Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Pages: 897–907. Copyright 2015, with permission from Elsevier.61
Abbreviations: CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.